These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153 [TBL] [Abstract][Full Text] [Related]
34. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770 [TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Penno G; Garofolo M; Del Prato S Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869 [TBL] [Abstract][Full Text] [Related]
36. Analysis from the EMPA-REG OUTCOME Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441 [TBL] [Abstract][Full Text] [Related]
37. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
38. Knockout of Na Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127 [TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2 Fujita H; Otomo H; Takahashi Y; Yamada Y Biochem Biophys Res Commun; 2022 Dec; 635():84-91. PubMed ID: 36265286 [TBL] [Abstract][Full Text] [Related]
40. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Rajasekeran H; Cherney DZ; Lovshin JA Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]